Aquestive Therapeutics Inc., a specialty pharmaceutical company based in Warren, N.J., has closed its IPO for gross proceeds of $67.5 million.

Priced at $15 apiece, the IPO offered 4.5 million common shares, which started trading on the Nasdaq on July 25 under the symbol AQST, according to a July 27 release. Aquestive has also given the underwriters an option to buy up to 675,000 additional common shares at the initial public offering price.

BMO Capital Markets and RBC Capital Markets acted as joint book-running managers for the offering. Wedbush PacGrow and JMP Securities acted as co-lead managers.

The company focuses on addressing unmet medical needs, specifically concerning central nervous system diseases.